Bios Life: AI Cancer Surveillance for 40M Americans

A new company, Bios Life, aims to transform cancer surveillance for 40 million Americans. This Boston-based firm, founded by former BioNTech executives, emerged from stealth with a $25 million seed round. Their plan is to replace traditional annual cancer screening with a continuously updated AI risk model. This model will be virtual, tailored to each patient's genome, history, and daily health signals. It will also be staffed by licensed clinicians nationwide. The founders, Ryan Richardson and Zach Taylor, are betting that AI technology used in drug discovery can now be applied directly to patients. Richardson chaired the board of InstaDeep, BioNTech's AI and machine learning subsidiary, which developed the genomics model at the heart of Bios Life's platform. The company highlights a gap in current cancer surveillance, noting that screening has been at a standstill for decades. About 18.6 million Americans are cancer survivors, and this population is growing faster than the infrastructure designed to monitor it. Bios Life's target includes these survivors and other high-risk individuals. This new approach could significantly change how cancer risk is monitored for a large population.